Smilow Cancer Hospital and Yale New Haven Health acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. Several types of quality measures have been approved by the Commission on Cancer. Evidence-based measures or accountability measures promote improvements in care delivery and are the highest standard for measurement. These measures demonstrate provider accountability, influence payment for services and promote transparency.
The latest accountability measures for breast and colon cancer at Smilow Cancer Hospital are listed below.
| Expected Estimated Performance Rates (%) | 2017 | 2018 | 2019 | |
| Tamoxifen or third generation aromotase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or stage IB-III hormone receptor positive breast cancer (Accountability) | 90% | 92.3% | 94.9% | 90.8% |
| Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes (Accountability) | 90% | 84.2% | 100% | 100% |
| Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability) | 90% | 93% | 95.1% | 94% |
| Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability) | 90% | 90.9% | 96.5% | 100% |
| Expected Estimated Performance Rates (%) |
2017 | 2018 | 2019 | |
| Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer (Accountability) | Not applicable | 95.7% | 95.8% | 92.1% |
